Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01167686
Other study ID # k008/2010
Secondary ID
Status Recruiting
Phase Phase 2
First received July 21, 2010
Last updated March 16, 2012
Start date March 2010
Est. completion date December 2012

Study information

Verified date March 2012
Source Meir Medical Center
Contact Assi Cicurel, MD
Phone 972-54-2401500
Email cicurels@gmail.com
Is FDA regulated No
Health authority Israel: Ministry of Health
Study type Interventional

Clinical Trial Summary

General:Prospective, randomized, double blind controlled trial of the food supplement GOLDTRAIN PLUS, to assess its safety and efficacy in comparison to placebo in subjects with upper respiratory infection.

Hypothesis: The food supplement GOLDTRAIN PLUS will be superior to placebo in shortening the time to recovery from the disease symptoms.

Study design and outcome measures:Study population of 182 generally healthy subjects with acute respiratory infection randomized in 1:1 ratio to active supplement versus placebo treatment, with randomization stratified by site. The study supplement administration will be continued for 7 days, and patient global assessment (PGA) will be the main primary measurement tool, based on a self-reporting questionnaire filled and monitored every 12 hours for 7 consecutive days. Throat and nasal swabs determining type of viral infection, will be taken at inclusion of patient and a number of blood tests at the end of treatment to look for any adverse effects of the medication.

Analysis and conclusion: All data-from the filled questionnaires, clinical follow up and laboratory studies will be analyzed by multivariate analysis to determine the efficacy of the supplement and its correlation to the clinical and laboratory parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 182
Est. completion date December 2012
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Signed Informed Consent

2. Age eligible (18 = Age = 90)

3. Respiratory infection with or without fever-

Exclusion Criteria:

1. Evidence of the bacterial infection

2. Symptoms suggestive of other than respiratory system illness (i.e. diarrhea, abdominal pain, skin rash, urinary symptoms).

3. Hospitalisation is planned

4. Surgery within previous 2 months

5. Pregnancy (women at childbirth age should have a urine beta-HCG test performed)

6. Subject with known renal dysfunction (creatinine = 2 mg/dL)

7. Subject has history of debilitating liver dysfunction with elevation of liver enzymes and bilirubin levels to = ULN

8. Participation in the active follow-up phase of another clinical study of an investigational drug or device

9. Known hypercalcemia -

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Gardemont Goldtrain Plus (GT+)
Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm

Locations

Country Name City State
Israel Revivim and Mashabei Sadeh Clalit Clinics Beer Sheba

Sponsors (3)

Lead Sponsor Collaborator
Meir Medical Center Ben-Gurion University of the Negev, Clalit Health Services

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Global Assessment (PGA) Patient global assessment (PGA) will be a primary measurement, based on the self-reporting answer to the following question: "What is your overall feeling as compared to the first day of treatment: worse, same or better". Time from the enrollment to the first 12 hours when the subject reports on a sustained improvement in symptoms (two consequent 12 hours periods) will be a primary outcome. The study supplement administration will be continued for 7 days. Seven days Yes
Secondary Rate of safety composite Death, hospitalizations, serious adverse effects 30 days Yes
See also
  Status Clinical Trial Phase
Completed NCT00369759 - An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants N/A
Completed NCT01907659 - Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections N/A
Completed NCT00388921 - High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM N/A
Completed NCT02211729 - A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children Phase 3
Recruiting NCT03093220 - Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis N/A
Completed NCT00514670 - A Randomized Controlled Trial of a School Disinfection and Hand Hygiene Program N/A
Completed NCT02438293 - 'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
Completed NCT02927743 - Effect of Evidence-based Reminders on Use of Antibiotics N/A
Completed NCT04362059 - A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 N/A
Completed NCT00533182 - Influenza in People With Normal and Weakened Immune Systems
Completed NCT01909128 - Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms Phase 3
Completed NCT00144040 - Improving Antibiotic Use in Acute Care Treatment N/A
Recruiting NCT05474430 - Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Completed NCT01443728 - Vitamin D for Sickle-cell Respiratory Complications Phase 2
Completed NCT02491164 - Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe Early Phase 1
Completed NCT01390753 - Role of Human Milk Bank in the Protection of Severe Respiratory Disease in Very Low Birth Weight Premature Infants N/A